Trial Profile
Investigation of Pharmacokinetics and Safety Profile of a Single Dose NNC0148-0287 C (Insulin 287) in Subjects With Various Degrees of Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Insulin icodec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 06 Oct 2023 Results assessing renal impairment affects the pharmacokinetic properties of insulin icodecpresented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2023 Primary endpoint has not been met, (AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single dose), as per presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2023 Results investigating if renal impairment affects the pharmacokinetics (PK) of icodec, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association